No Data
gf sec: The upstream prices of penicillin and cephalosporins are fluctuating at a high level, while the active pharmaceutical ingredient is finding a bottom and stabilizing.
According to the data from the National Bureau of Statistics, in September 2024, the month-on-month PPI value of chemical drug active pharmaceutical ingredient manufacturing was 97.10, an increase of 2.0 compared to the previous month, and an increase of 1.63 from the average of 95.47 in the first half of 2024. Since the year 2023, when the month-on-month PPI of active pharmaceutical ingredient manufacturing fell below 100 for the whole year, the recent PPI value has been in an increasing state, indicating that the overall price of active pharmaceutical ingredients is in a phase of slight bottoming and recovery.
Zhejiang Tianyu Pharmaceutical Co., Ltd. (SZSE:300702) Looks Inexpensive But Perhaps Not Attractive Enough
Ping An Securities: The supply and demand relationship of active pharmaceutical ingredients continues to improve, and the integration of formulations contributes to long-term growth.
According to IQVIA data, from 2024 to 2028, the global pharmaceutical sales facing patent cliffs and losses are approximately $192 billion, presenting a development opportunity for generic drugs and related specialty active pharmaceutical ingredient companies.
Tianyu Co., Ltd.: Report for the third quarter of 2024
Zhejiang Tianyu Pharmaceutical (300702.SZ): The net income for the first three quarters was 85.1141 million yuan, a year-on-year increase of 23.72%.
Gelonghui October 28th | zhejiang tianyu pharmaceutical (300702.SZ) released the third quarter report for 2024, achieving revenue of 1.932 billion yuan in the first three quarters, a year-on-year increase of 3.61%; net income attributable to the shareholders of the listed company was 85.1141 million yuan, a year-on-year increase of 23.72%; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 91.2987 million yuan, a year-on-year decrease of 30.67%; basic earnings per share were 0.24 yuan.
Zhejiang Tianyu Pharmaceutical (300702.SZ): Oterconazole active pharmaceutical ingredient passed the CDE review
Zhejiang Tianyu Pharmaceutical (300702.SZ) announced that the company's ketoconazole active pharmaceutical ingredient recently passed the National Medical Products Administration...
Further Weakness as Zhejiang Tianyu Pharmaceutical (SZSE:300702) Drops 11% This Week, Taking Three-year Losses to 64%
No Data
